What is asundexian and how does it work to prevent strokes?

Asundexian is an investigational oral anticoagulant that selectively inhibits clotting factor XIa, a protein mainly involved in the formation of harmful blood clots, without significantly impacting normal hemostasis.

What were the key findings of the OCEANIC-STROKE trial regarding asundexian?

The OCEANIC-STROKE trial demonstrated that asundexian reduced the risk of a second stroke by 26% in patients who had recently experienced a clot-related stroke or TIA, without increasing bleeding risk.

Is asundexian currently approved for clinical use?

No, asundexian is still investigational and has not yet been approved for clinical use; further evaluation and regulatory review are required.

Home / Health / New Stroke Drug Offers Hope Without Bleeding Risk

New Stroke Drug Offers Hope Without Bleeding Risk

27 Apr

•

Summary

Asundexian reduced recurrent stroke risk by 26% in a major trial.
The new drug targets clotting factor XIa, sparing normal bleeding control.
OCEANIC-STROKE trial included over 12,300 participants globally.

New Stroke Drug Offers Hope Without Bleeding Risk

A significant breakthrough in stroke prevention may be on the horizon with the investigational drug asundexian. New findings from the OCEANIC-STROKE Phase 3 trial reveal that this novel oral anticoagulant reduced the risk of a second stroke by 26% in individuals who had recently experienced a clot-related stroke or TIA. Crucially, this benefit was achieved without an associated increase in bleeding complications.

The international trial, which enrolled over 12,300 participants from 37 countries, focused on patients at high risk of recurrent stroke. Asundexian works by selectively inhibiting clotting factor XIa, a protein believed to be more critical for pathological clot formation than for normal hemostasis. This targeted mechanism differentiates it from existing anticoagulants that can impair the body's ability to stop bleeding.